medigraphic.com

2003, Number 1

<< Back Next >>

Rev Hosp M Gea Glz 2003; 6 (1)

Current treatment of the peripheral arterial occlusive disease

Porres AM, Gatica GLE, Porres MM

Language: Spanish
References: 54
Page: 31-39
PDF size: 79.63 Kb.


ABSTRACT

The peripheral arterial disease is defined as an important manifestation of systemic atherosclerosis, the severity is closely associated with the risk of myocardial infarction, ischemic stroke, and death from vascular causes. By the ankle-brachial index we can assess the long-term prognosis of the patients, because the lowest anklebrachial index, have an annual mortality of 25%. Inside the clinical manifestations the pivotal symptoms are pain affecting the calves, and one third of these patients have typical claudication.
The treatment of this disease focuses the modification of risk factors (smoking, hyperlipidemia, hypertension and diabetes mellitus) and a formal exercise program. The administration of drugs like aspirin, clopidogrel and cilostazol play an important role to improve the patient’s symptoms, such as the functional capacity and their quality of life.


REFERENCES

  1. Criqui MH, Fronck A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71:510-5.

  2. Hiatt WR, Hoag S, Hamman RF. Effect of diagnosis criteria on the prevalence of peripheral arterial disease: the San Luis Valley Diabetes Study. Circulation 1995;91:1472-9.

  3. Newman AB, Shemanski L, Manolio TA. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999;19:538-45.

  4. McKenna M, Wolfson S, Kuller R. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991;87:119-28.

  5. Vogt MT, McKenna M, Anderson SJ, Wolfson SK, Kuller LH. The relationship between ankle-arm index and mortality in older men and women. J Am Geriatr Soc 1993;41:523-30.

  6. Dormandy JA, Heeck L, Vig S. The fate of patients with critical leg ischemia. Semin Vasc Surg 1999;12:142-7.

  7. Graham IM, Daly LE, Refsum HM. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA 1997;277: 1775-81.

  8. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.

  9. Rose GA, Blackburn H. Cardiovascular survey methods. World Health Organization monograph series. No. 56. Geneva: World Health Organization, 1968.

  10. Imparato AM, Kim GE, Davidson T, Crowley JG. Intermittent claudication: it’s natural course. Surgery 1975;78:795-9.

  11. Orchard TJ, Strandness DE. Assessment of peripheral vascular disease in diabetes: report and recommendations of an international workshop sponsored by the American Diabetes Association and the American Heart Association September 18-20, 1992. New Orleans, Louisiana. Circulation 1993;88:819-28.

  12. Girolami B, Bernardi E, Prins MH. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline or nafronyl: a meta analysis. Arch Intern Med 1999;159:337-45.

  13. Khan F, Litchfield SJ, Belch JJ. Cutaneous microvascular responses are improved after cholesterol-lowering in patients with peripheral arterial disease and hypercholesterolemia. Adv Exp Med Biol 1997;428: 49-54.

  14. Kirk G, McLaren M, Muir AH, Stonebridge PA, Belch JJ. Decrease in P-selectin levels in patients with hypercholesterolemia and peripheral arterial occlusive disease after lipid-lowering treatment. Vasc Med 1999;4:23-6.

  15. Leng GC, Price JF, Jepson RG. Lipid-lowering for lower limb atherosclerosis (Cochrane review). In: The Cochrane library. Oxford, England: Update Software, 2001.

  16. Blankenhorn DH, Azen SP, Crawford DW. Effects of colestipolniacin therapy on human femoral atherosclerosis. Circulation 1991;83:438-47.

  17. Kroon AA, van Asten WN, Stalenhoef AF. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 1996;125:945-54.

  18. Ansell BJ, Watson KE, Fogelman AM. An evidence-based assessment of NCEP Adult Treatment Panel II guidelines: National Cholesterol Education Program. JAMA 1999;282:2051-7.

  19. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995;75:894-903.

  20. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

  21. Solomon SA, Ramsay LE, Yeo WW, Parnell L, Morris-Jones W. Beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. BMJ 1991;303:1100-4.

  22. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials. Arch Intern Med 1991;151:1769-76.

  23. Heintzen MP, Strauer BE. Peripheral vascular effects of betablockers. Eur Heart J 1994;15:Suppl C:2-7.

  24. The Heart Outcomes Prevention Evaluation Study Investigators (HOPE). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.

  25. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-50.

  26. Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340:1449-54.

  27. Westendorp IC, in’t Veld BA, Grobbee DE. Hormone replacement therapy and peripheral arterial disease: the Rotterdam study. Arch Intern Med 2000;160:2498-502.

  28. Timaran CH, Stevens SL, Grandas OH, Piercy KT, Freeman MB, Goldman MH. Influence of hormone replacement therapy on graft patency after femoropopliteal bypass grafting. J Vasc Surg 2000;32:506-18.

  29. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.

  30. Sachdev GP, Ohlogge KD, Johnson CL. Review of the Fifth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy: outpatient management for adults. Am J Health Syst Pharm 1999;56:1505-14.

  31. Collaborative overview of randomized trials of antiplatelet therapy. II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994;308:159-68.

  32. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med 1998;128:541-4.

  33. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.

  34. Balsano F, Violi F. Effect of picotamide on the clinical progression of peripheral vascular disease: a double blind placebo-controlled study. Circulation 1993;87:1563-9.

  35. Randomized placebo-controlled, double blind trial of ketanserin in claudicants: changes in claudication distance and ankle systolic pressure: PACK Claudication Substudy. Circulation 1989;89: 1544-8.

  36. Khaira HS, Hanger R, Shearman CP. Quality of life in patients with intermittent claudication. Eur J Vasc Endovasc Surg 1996;11:65-9.

  37. Zetterquist S. The effect of active training on the nutritive blood flow in exercising ischemic legs. Scand J Clin Lab Invest 1970;25: 101-11.

  38. Hiatt WR, Regensteiner JG, Wolfel EE, Carry MR, Brass EP. Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease. J Appl Physiol 1996;81:780-8.

  39. Regensteiner JG, Meyer TJ, Krupski WC, Cranford LS, Hiatt WR. Hospital versus home-based exercise rehabilitation for patients with peripheral arterial occlusive disease. Angiology 1997;48:291-300.

  40. Coffman JD. Vasodilator drugs in peripheral vascular disease. N Engl J Med 1979;300: 713-7.

  41. Samlaska CP, Winfield EA. Pentoxifylline. J Am Acad Dermatol 1994;30: 603-21.

  42. Porter JM, Cutler BS, Lee BY. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982;104:66-72.

  43. Kohda N, Tani T, Nakayama S, et al. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb Res 1999;96:261-8.

  44. Tsuchikane E, Fukuhara A, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 1999;100:21-6.

  45. Cone J, Wang S, Tandon N, et al. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol 1999;34:497-504.

  46. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000;109:523-30.

  47. Dawson DL, Cutler BS, Meissner MH, Strandnesss DEJ. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998;98:678-86.

  48. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999;159:2041-50.

  49. Money SR, Herd JA, Issacohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998;27:267-74.

  50. Lehert P, Comte S, Gamand S, Brown TM. Naftidrofuryl in intermittent claudication: a retrospective analysis. J Cardiovasc Pharmacol 1994;23:Suppl 3:S48-S52.

  51. Brass EP, Hiatt WR, Gardner AW, Hoppel CL. Decreased NADH dehydrogenase and ubiquinol-cytochrome c oxidoreductase in peripheral arterial disease. Am J Physiol Heart Circ Physiol 2001;280:H603-H609.

  52. Hiatt WR, Wolfel EE, Regensteiner JG, Brass EP. Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. J Appl Physiol 1992;73:346-53.

  53. Brevetti G, Perna S, Sabba C, et al. Superiority of L-propionylcarnitine versus L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, doubleblind, cross over study. Eur Heart J 1992;13:251-5.

  54. Lievre M, Morand S, Besse B, Fiessinger JN, Boissel JP. Oral beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double blind, randomized, multicenter controlled trial. Circulation 2000;102:426-31.




2020     |     www.medigraphic.com